IM Cannabis (IMCC) Income from Continuing Operations (2020 - 2026)
IM Cannabis (IMCC) posted quarterly Income from Continuing Operations of 1828847.88 for Q1 2026, down 1897.4% year-over-year from 101749.81 in Q1 2025, and up 75.48% quarter-over-quarter from 7459131.52 in Q4 2025.
IM Cannabis (IMCC) Income from Continuing Operations (2020 - 2026) Analysis & Trends
IM Cannabis' Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 1828847.88 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 1897.4% year-over-year to 1828847.88; the TTM figure through Mar 2026 stood at 12995677.45 (down 1083.64% YoY), while the FY2025 annual figure was 10244294.64, down 15.12% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 1828847.88, up from 7459131.52 in the prior quarter.
- The five-year high for Income from Continuing Operations was 3162061.52 in Q3 2022, with the low at 31126435.92 in Q4 2022.
- The 5-year median for Income from Continuing Operations is 1828847.88 (2026), against an average of 4149556.02.
- The sharpest annual moves came in 2022 and 2026: Income from Continuing Operations jumped 164.38% in 2022, then plunged 1897.4% in 2026.
- IM Cannabis' Income from Continuing Operations stood at 31126435.92 in 2022, then soared by 56.74% to 13465505.28 in 2023, then soared by 91.36% to 1163254.85 in 2024, then sank by 541.23% to 7459131.52 in 2025, then jumped by 75.48% to 1828847.88 in 2026.
- Business Quant data shows IMCC's Income from Continuing Operations at 1828847.88 in Q1 2026, 7459131.52 in Q4 2025, and 2808444.29 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.85 Bn | 42.88 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.02 Bn | 39.37 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.47 Bn | 29.79 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.59 Bn | 22.79 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.20 Bn | 19.53 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.45 Bn | 15.06 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | - |
| 10 | IM Cannabis | 537,472.00 | -631,498.17 | 1.09 Mn | -3.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.17 Mn |
| Mar 31, 2026 | -1.83 Mn |
| Dec 31, 2025 | -7.46 Mn |
| Sep 30, 2025 | -2.81 Mn |
| Jun 30, 2025 | -899,253.77 |
| Mar 31, 2025 | 101,749.81 |
| Dec 31, 2024 | -1.16 Mn |
| Sep 30, 2024 | -793,163.79 |
| Jun 30, 2024 | 756,730.47 |
| Mar 31, 2024 | -4.55 Mn |
| Dec 31, 2023 | -13.47 Mn |
| Sep 30, 2023 | 1.59 Mn |
| Jun 30, 2023 | -2.76 Mn |
| Mar 31, 2023 | -652,412.19 |
| Dec 31, 2022 | -31.13 Mn |
| Sep 30, 2022 | 3.16 Mn |
| Jun 30, 2022 | -2.90 Mn |
| Mar 31, 2022 | -5.75 Mn |
| Dec 31, 2021 | -2.89 Mn |
| Sep 30, 2021 | -4.91 Mn |